Cancer Health Treatment Update Coronavirus Changes Cancer Care Nearly one in four people with cancer have delayed care, including nonurgent surgery.  FDA Approves Zepzelca for Metastatic Small-Cell Lung Cancer Lurbinectedin shrank tumors in a third of people with this less common type of lung cancer. U.S. Cancer Care Costs Projected to Exceed $245 Billion by 2030 The estimated national costs for cancer-related medical care and oral prescriptions drugs in 2030 will be $221 billion and $25 billion, respectively. Cancer Rehabilitation This team approach aims to improve both your ability to function and your quality of life. Inexpensive Steroid Is First Drug Shown to Reduce COVID-19 Deaths Dexamethasone reduced mortality by up to a third among severely ill patients who needed supplemental oxygen or ventilators. For all of Cancer Health's coverage of the novel coronavirus and COVID-19, including how they affect people living with cancer, click here. ASCO Annual Meeting Goes Virtual See all our reports from the American Society of Clinical Oncology's virtual scientific program. Cancer Health Summer 2020 Check out our new print edition! Advertisement Newsfeed U.S. Cancer Care Costs Projected to Exceed $245 Billion by 2030 NIH Scientists Develop Blood Test to Help Improve Liver Cancer Screening COVID-19 May Initially Affect the Entire Nervous System An Ode to Community During Cancer and Coronavirus Blog: Food and Drug Administration (FDA) FDA Approves Opdivo for Esophageal Cancer FDA Approves Cyramza Plus Tarceva for First-Line Lung Cancer Treatment FDA Approves Opdivo Plus Yervoy With Chemotherapy for Metastatic Lung Cancer FDA Approves Alunbrig for ALK-Positive Metastatic Non-Small-Cell Lung Cancer Newsfeed U.S. Cancer Care Costs Projected to Exceed $245 Billion by 2030 NIH Scientists Develop Blood Test to Help Improve Liver Cancer Screening COVID-19 May Initially Affect the Entire Nervous System An Ode to Community During Cancer and Coronavirus Blog: Food and Drug Administration (FDA) FDA Approves Opdivo for Esophageal Cancer FDA Approves Cyramza Plus Tarceva for First-Line Lung Cancer Treatment FDA Approves Opdivo Plus Yervoy With Chemotherapy for Metastatic Lung Cancer FDA Approves Alunbrig for ALK-Positive Metastatic Non-Small-Cell Lung Cancer

You are receiving this email because you opted in at one of our websites. At your request, this message was sent to newsletter@newslettercollector.com by update@cancerhealth.com. Please remember to add update@cancerhealth.com to your email address book, so that these updates aren't blocked as spam.

To change your subscription information and preferences, please visit your personal preferences page. Or you can unsubscribe completely from this list.

To forward this message, please do not use the forward button of your email application, because this message was made specifically for you only. Instead use the forward page in our newsletter system.

Did you receive this email from a friend? You can subscribe and you will receive our next newsletter directly to your inbox.

Our mailing address is: